Effectiveness of combined phacoemulsification with modified trabeculopuncture in patient with primary open-angle glaucoma

Session Details

Session Title: Combined Cataract Surgery Techniques. Surgical Devices

Session Date/Time: Saturday 05/09/2015 | 08:30-10:30

Paper Time: 08:36

Venue: Main Auditorium

First Author: : V.Melnyk UKRAINE

Co Author(s): :                        

Abstract Details

Purpose:

To assess effectiveness of combined phacoemulsification with modified trabeculopuncture in patient with primary open-angle glaucoma during two years after operation.

Setting:

634 patients (746 eyes) with primary open-angle glaucoma were operated. Ophthalmologic Clinic VISIOBUD and Hospital MEDBUD, Chervonozoryaniy ,Kiev, Ukraine

Methods:

All patients were divided on two groups. The first group of patients (201 eyes) were performed phacoemulsification with trabeculopuncture. The second group of patients (545 eyes) we performed phacoemulsification with modified trabeculopuncture. The main difference of the second technique is implanting of rests of capsular bag into the space of Schlemm's canal. We examined all patients every two months during two year after operation.

Results:

The main task of implanting of rests of capsular bag into the space of Schlemm's canal is to prevent adhesion of walls of Schlemm's canal. The mean ocular pressure in the first group of patients was 21,45 mm.Hg. The mean ocular pressure in the second group of patients was 17,12mm.Hg. We observed narrowing of visual field in the first group of patients on 7,4%, and in the second group on 2,2%. During two years examination necessity of secondary antiglaucoma operation in the first group was 23% (46eyes), but in the second group it was necessary to perform new antiglaucoma operation only in 4% cases.

Conclusions:

Combined phacoemulsification with modified trabeculopuncture is the operation of choice in patients with primary open-angle glaucoma. It allows to keep IOP and visual field of glaucoma patients and decreases risk of secondary antiglaucoma operations.

Financial Interest:

NONE